{
    "organizations": [],
    "uuid": "a3ef75274d938f4078936e5071ebf7bdd44310f6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-expects-cost-cuts-rising/brief-novartis-expects-cost-cuts-rising-entresto-cosentyx-sales-to-help-meet-2018-op-profit-targets-idUSFWN1RW0HD",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis expects cost cuts, rising Entresto, Cosentyx sales to help meet 2018 op. profit targets",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - Novartis AG:\n* CEO SAYS BELIEVES COSENTYX SALES FOR FULL YEAR WILL BE IN LINE WITH CONSENSUS, HAD SOME DESTOCKING BY SPECIALTY PHARMA IN Q1 BUT BELIEVES DRUG WILL OVERCOME THAT\n* CEO SAYS SANDOZ HAD A TOUGH FIRST QUARTER, STRONG PERFORMANCE OUTSIDE US BUT CONTINUED PRICE PRESSURES THERE, LOOKING FORWARD TO UPCOMING BIOSIMILARS LAUNCHES\n* CEO SAYS ALCON ON NICE GROWTH TRAJECTORY, NOVARTIS REMAINS ON COURSE FOR POTENTIAL CAPITAL MARKETS ACTION IN 2019\n* CEO SAYS CONTINUES TO LOOK FOR BOLT-ON ACQUISITIONS IN CORE THERAPEUTIC AREAS, NEW TECHNOLOGY PLATFORMS\n* CEO SAYS WILL CONTINUE TO EVALUATE ORAL SOLIDS BUSINESS AT SANDOZ IN UNITED STATES, NO DECISIONS MADE YET\n* CEO SAYS KYRIAH OFF TO A SOLID START IN PEDIATRIC ALL, EXPECTS DLBCL APPROVAL IN US, EUROPE LATER THIS YEAR, REMAINS CONFIDENT WILL BE A BLOCKBUSTER MEDICINE\n* CEO SAYS ENTRESTO SALES GROWTH, COST CUTS, CONTINUED ALCON DEVELOPMENT WILL HELP SPUR CORE OPERATING PROFIT IMPROVEMENTS IN 2018 COMPARED TO Q1\n* CEO SAYS CURRENTLY SEARCHING FOR NEW HEAD OF BUSINESS SERVICES, BUT FEELS GOOD WITH WHERE NOVARTIS IS AS A TEAM FOLLOWING JOHN TSAIâ€™S APPOINTMENT AS NEW DRUG DEVELOPMENT CHIEF, CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Reporting by John Miller)\n ",
    "published": "2018-04-19T18:51:00.000+03:00",
    "crawled": "2018-04-20T12:05:07.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "novartis",
        "ag",
        "ceo",
        "say",
        "belief",
        "cosentyx",
        "sale",
        "full",
        "year",
        "line",
        "consensus",
        "destocking",
        "specialty",
        "pharma",
        "q1",
        "belief",
        "drug",
        "overcome",
        "ceo",
        "say",
        "sandoz",
        "tough",
        "first",
        "quarter",
        "strong",
        "performance",
        "outside",
        "u",
        "continued",
        "price",
        "pressure",
        "looking",
        "forward",
        "upcoming",
        "biosimilars",
        "launch",
        "ceo",
        "say",
        "alcon",
        "nice",
        "growth",
        "trajectory",
        "novartis",
        "remains",
        "course",
        "potential",
        "capital",
        "market",
        "action",
        "ceo",
        "say",
        "continues",
        "look",
        "acquisition",
        "core",
        "therapeutic",
        "area",
        "new",
        "technology",
        "platform",
        "ceo",
        "say",
        "continue",
        "evaluate",
        "oral",
        "solid",
        "business",
        "sandoz",
        "united",
        "state",
        "decision",
        "made",
        "yet",
        "ceo",
        "say",
        "kyriah",
        "solid",
        "start",
        "pediatric",
        "expects",
        "dlbcl",
        "approval",
        "u",
        "europe",
        "later",
        "year",
        "remains",
        "confident",
        "blockbuster",
        "medicine",
        "ceo",
        "say",
        "entresto",
        "sale",
        "growth",
        "cost",
        "cut",
        "continued",
        "alcon",
        "development",
        "help",
        "spur",
        "core",
        "operating",
        "profit",
        "improvement",
        "compared",
        "q1",
        "ceo",
        "say",
        "currently",
        "searching",
        "new",
        "head",
        "business",
        "service",
        "feel",
        "good",
        "novartis",
        "team",
        "following",
        "john",
        "tsai",
        "appointment",
        "new",
        "drug",
        "development",
        "chief",
        "chief",
        "medical",
        "officer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "john",
        "miller"
    ]
}